Imagine you are reviewing a client’s portfolio transition for the upcoming financial year. A client holds a substantial position in an international feeder fund, which falls under the 'Specified Mutual Fund'...
Imagine you are reviewing a portfolio strategy for a high-net-worth client who has just received a rights entitlement notice from a blue-chip company. Your client is debating whether to renounce these rights or exercise...
Imagine you are reviewing a client’s trading ledger at the end of the financial year. You notice several ‘out-of-the-money’ call options that were purchased for hedging purposes but were never exercised, eventually...
Imagine you are drafting an advisory note for a client whose portfolio includes units in a mutual fund scheme currently undergoing liquidation. While the client is understandably anxious about the return of capital, your...
Imagine you are an investment advisor reviewing a client’s portfolio that includes an old, underperforming close-ended debt scheme nearing its maturity. Suddenly, you receive notice that the fund house has decided to...
Imagine you are an equity research analyst reviewing the portfolio of a high-net-worth client who held units in a specific sectoral mutual fund that was recently wound up by the AMC. The client is confused, assuming that...
Imagine you are reviewing a portfolio restructuring proposal for a high-net-worth client. The asset management company (AMC) intends to merge a small-cap equity fund with a liquid debt fund to streamline their product...
Imagine you are reviewing the consolidated financial position of a high-net-worth client who has diversified their holdings by settling assets into an offshore trust. While your primary task is assessing the volatility...
Imagine you are advising a young professional who has been diligently contributing to a Sukanya Samriddhi Account (SSA) for his daughter. As the daughter approaches age 18, the client asks whether he should trigger the...
Imagine you are an equity analyst at a brokerage firm preparing a report on a major pharmaceutical sector consolidation. One of your covered companies, PharmaCorp, is being amalgamated into a larger entity, BioGlobal....